Oscillatory haematopoiesis in adults with sickle cell disease treated with hydroxycarbamide

John H. Baird, Caterina P. Minniti, Jung Min Lee, Xin Tian, Colin Wu, Mary Jackson, Shoaib Alam, James G. Taylor, Gregory J. Kato

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Summary: Hydroxycarbamide therapy has been associated with significant oscillations in peripheral blood counts from myeloid, lymphoid and erythroid lineages in patients with polycythaemia vera and chronic myeloid leukaemia. We retrospectively evaluated serial blood counts over an 8-year period from 44 adult patients with sickle cell disease receiving hydroxycarbamide. Platelet counts, leucocyte counts, haemoglobin values and reticulocyte counts, apportioned by hydroxycarbamide status, were analysed using a Lomb-Scargle periodogram algorithm. Significant periodicities were present in one or more counts in 38 patients receiving hydroxycarbamide for a mean duration of 4·81 years. Platelet and leucocyte counts oscillated in 56·8% and 52·3% of patients, respectively. These oscillations generally became detectable within days of initiating therapy. During hydroxycarbamide therapy, the predominant periods of oscillation were 27 ± 1 d for platelet counts and 15 ± 1 d for leucocyte counts. Despite an absolute decrease in leucocyte and platelet counts during hydroxycarbamide treatment, the amplitudes between nadirs and zeniths remained similar regardless of exposure. Our observations appear consistent with previously proposed models of cyclic haematopoiesis, and document that hydroxycarbamide-induced oscillations in blood counts are innocuous phenomena not limited to myeloproliferative disorders as described previously. We speculate the known cell cycle inhibitory properties of hydroxycarbamide may accentuate otherwise latent constitutive oscillatory haematopoiesis.

Original languageEnglish (US)
Pages (from-to)737-746
Number of pages10
JournalBritish Journal of Haematology
Volume168
Issue number5
DOIs
StatePublished - Mar 1 2015
Externally publishedYes

Fingerprint

Hematopoiesis
Sickle Cell Anemia
Platelet Count
Leukocyte Count
Reticulocyte Count
Myeloproliferative Disorders
Polycythemia Vera
Periodicity
Therapeutics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cell Cycle
Hemoglobins

Keywords

  • Complete peripheral blood count
  • Hydroxycarbamide
  • Oscillatory haematopoiesis
  • Periodicity
  • Sickle cell disease

ASJC Scopus subject areas

  • Hematology
  • Medicine(all)

Cite this

Oscillatory haematopoiesis in adults with sickle cell disease treated with hydroxycarbamide. / Baird, John H.; Minniti, Caterina P.; Lee, Jung Min; Tian, Xin; Wu, Colin; Jackson, Mary; Alam, Shoaib; Taylor, James G.; Kato, Gregory J.

In: British Journal of Haematology, Vol. 168, No. 5, 01.03.2015, p. 737-746.

Research output: Contribution to journalArticle

Baird, JH, Minniti, CP, Lee, JM, Tian, X, Wu, C, Jackson, M, Alam, S, Taylor, JG & Kato, GJ 2015, 'Oscillatory haematopoiesis in adults with sickle cell disease treated with hydroxycarbamide', British Journal of Haematology, vol. 168, no. 5, pp. 737-746. https://doi.org/10.1111/bjh.13203
Baird, John H. ; Minniti, Caterina P. ; Lee, Jung Min ; Tian, Xin ; Wu, Colin ; Jackson, Mary ; Alam, Shoaib ; Taylor, James G. ; Kato, Gregory J. / Oscillatory haematopoiesis in adults with sickle cell disease treated with hydroxycarbamide. In: British Journal of Haematology. 2015 ; Vol. 168, No. 5. pp. 737-746.
@article{6a55a9f7fc8242b2ac9ff6973def20e8,
title = "Oscillatory haematopoiesis in adults with sickle cell disease treated with hydroxycarbamide",
abstract = "Summary: Hydroxycarbamide therapy has been associated with significant oscillations in peripheral blood counts from myeloid, lymphoid and erythroid lineages in patients with polycythaemia vera and chronic myeloid leukaemia. We retrospectively evaluated serial blood counts over an 8-year period from 44 adult patients with sickle cell disease receiving hydroxycarbamide. Platelet counts, leucocyte counts, haemoglobin values and reticulocyte counts, apportioned by hydroxycarbamide status, were analysed using a Lomb-Scargle periodogram algorithm. Significant periodicities were present in one or more counts in 38 patients receiving hydroxycarbamide for a mean duration of 4·81 years. Platelet and leucocyte counts oscillated in 56·8{\%} and 52·3{\%} of patients, respectively. These oscillations generally became detectable within days of initiating therapy. During hydroxycarbamide therapy, the predominant periods of oscillation were 27 ± 1 d for platelet counts and 15 ± 1 d for leucocyte counts. Despite an absolute decrease in leucocyte and platelet counts during hydroxycarbamide treatment, the amplitudes between nadirs and zeniths remained similar regardless of exposure. Our observations appear consistent with previously proposed models of cyclic haematopoiesis, and document that hydroxycarbamide-induced oscillations in blood counts are innocuous phenomena not limited to myeloproliferative disorders as described previously. We speculate the known cell cycle inhibitory properties of hydroxycarbamide may accentuate otherwise latent constitutive oscillatory haematopoiesis.",
keywords = "Complete peripheral blood count, Hydroxycarbamide, Oscillatory haematopoiesis, Periodicity, Sickle cell disease",
author = "Baird, {John H.} and Minniti, {Caterina P.} and Lee, {Jung Min} and Xin Tian and Colin Wu and Mary Jackson and Shoaib Alam and Taylor, {James G.} and Kato, {Gregory J.}",
year = "2015",
month = "3",
day = "1",
doi = "10.1111/bjh.13203",
language = "English (US)",
volume = "168",
pages = "737--746",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Oscillatory haematopoiesis in adults with sickle cell disease treated with hydroxycarbamide

AU - Baird, John H.

AU - Minniti, Caterina P.

AU - Lee, Jung Min

AU - Tian, Xin

AU - Wu, Colin

AU - Jackson, Mary

AU - Alam, Shoaib

AU - Taylor, James G.

AU - Kato, Gregory J.

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Summary: Hydroxycarbamide therapy has been associated with significant oscillations in peripheral blood counts from myeloid, lymphoid and erythroid lineages in patients with polycythaemia vera and chronic myeloid leukaemia. We retrospectively evaluated serial blood counts over an 8-year period from 44 adult patients with sickle cell disease receiving hydroxycarbamide. Platelet counts, leucocyte counts, haemoglobin values and reticulocyte counts, apportioned by hydroxycarbamide status, were analysed using a Lomb-Scargle periodogram algorithm. Significant periodicities were present in one or more counts in 38 patients receiving hydroxycarbamide for a mean duration of 4·81 years. Platelet and leucocyte counts oscillated in 56·8% and 52·3% of patients, respectively. These oscillations generally became detectable within days of initiating therapy. During hydroxycarbamide therapy, the predominant periods of oscillation were 27 ± 1 d for platelet counts and 15 ± 1 d for leucocyte counts. Despite an absolute decrease in leucocyte and platelet counts during hydroxycarbamide treatment, the amplitudes between nadirs and zeniths remained similar regardless of exposure. Our observations appear consistent with previously proposed models of cyclic haematopoiesis, and document that hydroxycarbamide-induced oscillations in blood counts are innocuous phenomena not limited to myeloproliferative disorders as described previously. We speculate the known cell cycle inhibitory properties of hydroxycarbamide may accentuate otherwise latent constitutive oscillatory haematopoiesis.

AB - Summary: Hydroxycarbamide therapy has been associated with significant oscillations in peripheral blood counts from myeloid, lymphoid and erythroid lineages in patients with polycythaemia vera and chronic myeloid leukaemia. We retrospectively evaluated serial blood counts over an 8-year period from 44 adult patients with sickle cell disease receiving hydroxycarbamide. Platelet counts, leucocyte counts, haemoglobin values and reticulocyte counts, apportioned by hydroxycarbamide status, were analysed using a Lomb-Scargle periodogram algorithm. Significant periodicities were present in one or more counts in 38 patients receiving hydroxycarbamide for a mean duration of 4·81 years. Platelet and leucocyte counts oscillated in 56·8% and 52·3% of patients, respectively. These oscillations generally became detectable within days of initiating therapy. During hydroxycarbamide therapy, the predominant periods of oscillation were 27 ± 1 d for platelet counts and 15 ± 1 d for leucocyte counts. Despite an absolute decrease in leucocyte and platelet counts during hydroxycarbamide treatment, the amplitudes between nadirs and zeniths remained similar regardless of exposure. Our observations appear consistent with previously proposed models of cyclic haematopoiesis, and document that hydroxycarbamide-induced oscillations in blood counts are innocuous phenomena not limited to myeloproliferative disorders as described previously. We speculate the known cell cycle inhibitory properties of hydroxycarbamide may accentuate otherwise latent constitutive oscillatory haematopoiesis.

KW - Complete peripheral blood count

KW - Hydroxycarbamide

KW - Oscillatory haematopoiesis

KW - Periodicity

KW - Sickle cell disease

UR - http://www.scopus.com/inward/record.url?scp=84922782758&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922782758&partnerID=8YFLogxK

U2 - 10.1111/bjh.13203

DO - 10.1111/bjh.13203

M3 - Article

C2 - 25377027

AN - SCOPUS:84922782758

VL - 168

SP - 737

EP - 746

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 5

ER -